GLP-1 Peptides: Heart Benefits Explained
New research reveals how GLP-1 peptides deliver cardiovascular benefits beyond weight loss. Here's what preclinical and clinical studies found.
Section
The knowledge base: peptide science from first principles.
Looking for background? Browse the peptide research library — cited overviews of every compound, sorted by evidence tier.
New research reveals how GLP-1 peptides deliver cardiovascular benefits beyond weight loss. Here's what preclinical and clinical studies found.
A new meta-analysis examines tesamorelin efficacy and safety in people living with HIV and lipodystrophy. Here's what the preclinical and clinical data show.
A 2025 meta-analysis examines semaglutide's effects on metabolic liver disease. Here's what placebo-controlled trial data actually show.
Two major systematic reviews examine teriparatide for pediatric hypoparathyroidism and postmenopausal osteoporosis. Here's what the evidence shows.
New research examines how negative controls are used in GLP-1 receptor agonist studies, revealing key gaps in real-world pharmacoepidemiology methods.
Do research peptides like BPC-157 and TB-500 work? An honest look at the animal data, the missing human trials, purity risks, and the FDA's 2026 review.
GLP-1, GIP, glucagon, and amylin power the new obesity drugs. A clear guide to what each hormone does and what dual, triple, and unimolecular agonists mean.
How is a peptide drug like semaglutide made? A guide to solid-phase peptide synthesis, purification, and how AI tools like RFpeptides are rewriting step one.
What is a peptide, and why do peptide drugs like semaglutide and insulin dominate medicine? A clear, jargon-free explainer on how peptides work as therapeutics.
Why are peptide drugs like semaglutide injected, not swallowed? A clear guide to gut absorption, drug half-life, and how oral GLP-1 pills finally cracked it.
The Explainers section of Peptide News Network is described as 'the knowledge base: peptide science from first principles.' It is designed to translate peer-reviewed science and medicine into accessible content for a general audience. Each story in the publication cites its primary sources, with a focus on peptide science, regulation, and industry topics.
According to Peptide News Network's Explainers section, the four gut hormones central to current metabolic medicine are GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), glucagon, and amylin. The publication notes that every headline drug in metabolic medicine is built from this same short list of hormones.
Peptide News Network's Explainers coverage indicates that companies keep combining GLP-1, GIP, glucagon, and amylin because each hormone plays a distinct role in metabolic regulation. By targeting multiple hormonal pathways simultaneously, drug developers aim to address the complexity of metabolic conditions. The publication presents this as a key theme in current metabolic medicine research and industry development.
No. Peptide News Network explicitly states that nothing published on the site is medical advice, and the publication directs readers to consult a licensed clinician before making any health decisions. This disclaimer applies across all content, including the Explainers section. Readers should always seek guidance from a qualified healthcare professional for individual health concerns.
Peptide News Network states that every story cites its primary sources, and the publication describes itself as focused on peer-reviewed science translated for a general audience. The Explainers section is specifically framed as a knowledge base built from first principles of peptide science, grounding its content in authoritative scientific and medical literature.
This content is for informational purposes only and is not medical advice. Consult a qualified healthcare professional for any medical concerns, diagnosis, or treatment.